2fo4: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 1: Line 1:
[[Image:2fo4.gif|left|200px]]
{{Seed}}
[[Image:2fo4.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_2fo4|  PDB=2fo4  |  SCENE=  }}  
{{STRUCTURE_2fo4|  PDB=2fo4  |  SCENE=  }}  


'''Enhanced MHC class I binding and immune responses through anchor modification of the non-canonical tumor associated MUC1-8 peptide'''
===Enhanced MHC class I binding and immune responses through anchor modification of the non-canonical tumor associated MUC1-8 peptide===




==Overview==
<!--  
Designing peptide-based vaccines for therapeutic applications in cancer immunotherapy requires detailed knowledge of the interactions between the antigenic peptide and major histocompatibility complex (MHC) in addition to that between the peptide-MHC complex and the T-cell receptor. Past efforts to immunize with high-affinity tumour-associated antigenic peptides have not been very immunogenic, which may be attributed to the lack of T cells to these peptides, having been deleted during thymic development. For this reason, low-to-medium affinity non-canonical peptides represent more suitable candidates. However, in addition to the difficulty in identifying such antigens, peptide binding to MHC, and hence its ability to induce a strong immune response, is limited. Therefore, to enhance binding to MHC and improve immune responses, anchor modifications of non-canonical tumour-associated peptides would be advantageous. In this study, the non-canonical tumour-associated peptide from MUC1, MUC1-8 (SAPDTRPA), was modified at the MHC anchor residues to SAPDFRPL (MUC1-8-5F8L) and showed enhanced binding to H-2Kb and improved immune responses. Furthermore, the crystal structure of MUC1-8-5F8L in complex with H-2Kb was determined and it revealed that binding of the peptide to MHC is similar to that of the canonical peptide OVA8 (SIINFEKL).
The line below this paragraph, {{ABSTRACT_PUBMED_17067310}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 17067310 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_17067310}}


==About this Structure==
==About this Structure==
Line 30: Line 34:
[[Category: Non-canonical peptide]]
[[Category: Non-canonical peptide]]
[[Category: Vaccine design]]
[[Category: Vaccine design]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May  4 04:07:13 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Tue Jul 29 06:21:47 2008''

Revision as of 03:21, 29 July 2008

File:2fo4.png

Template:STRUCTURE 2fo4

Enhanced MHC class I binding and immune responses through anchor modification of the non-canonical tumor associated MUC1-8 peptide

Template:ABSTRACT PUBMED 17067310

About this Structure

2FO4 is a Protein complex structure of sequences from Mus musculus. Full crystallographic information is available from OCA.

Reference

Enhanced major histocompatibility complex class I binding and immune responses through anchor modification of the non-canonical tumour-associated mucin 1-8 peptide., Lazoura E, Lodding J, Farrugia W, Ramsland PA, Stevens J, Wilson IA, Pietersz GA, Apostolopoulos V, Immunology. 2006 Nov;119(3):306-16. PMID:17067310

Page seeded by OCA on Tue Jul 29 06:21:47 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=2fo4&oldid=730748"